Many promising microbicide candidates are proteins or peptides, including neutralizing monoclonal antibodies (mAbs). Here, the expression of the HIV-neutralizing mAb b12 in transgenic plants is described. The plant-derived mAb b12 was shown to have gp120 binding activity and HIV-neutralizing activity in vitro. However, it is likely that a protein-based microbicide will need to comprise a combination of two or more products, in order to provide long-lasting and cross-clade protection. Building on the expression of mAb b12 and to address the need for a combinational agent, the expression of a fusion protein of mAb b12 with cyanovirin-N, another protein microbicide, has been explored. This fusion protein molecule is predicted to have four binding sites for HIV gp120 with two different specificities. The fusion protein was assembled and expressed in planta, and functionality was confirmed by gp120 binding and HIV neutralization in vitro. Each moiety of the fusion protein retained its binding ability to gp120. In addition, this fusion protein demonstrated increased anti-HIV potency compared to b12 or CV-N alone. This fusion protein addresses the requirement to combine microbicide products, and the production in plants is a step toward resolving the issues of manufacturing scalability and cost for developing countries. Sexton, A., Harman, S., Shattock, R. J., Ma, J. K.-C. Design, expression, and characterization of a multivalent, combination HIV microbicide. 
Microbicides are products that can be applied prior to sexual intercourse to prevent the transmission of HIV and represent an important prevention strategy to curtail the HIV pandemic (1) . Many promising microbicide candidates are proteins or peptides; however, the success of using such molecules is likely to be determined by the ability to produce sufficiently large quantities to cope with global demand. Estimations based on a 5-mg protein microbicide dose administered twice a week suggest that a production capacity of 5000 kg/yr is required to supply just 10 million women (2) . This is complicated by the likelihood that an effective microbicide will need to consist of a combination of antiviral molecules to prevent the rapid evolution of HIV resistance and to provide sufficient cross-clade protection. Manufacturing scalability and capacity are important issues, but it is also imperative that the microbicide is produced at low cost to ensure availability of these products in the developing world.
Many proteins and peptides have been successfully expressed using transgenic plants. Plant expression systems possess many advantages for the production of pharmaceutically important proteins, some of which are particularly important in the context of protein microbicide production. Not only could plant production be readily scaled up, but the advantages of storage and distribution (in naturally robust and stable seeds) and the potential for formulation using minimally processed plant preparations means that this production system could offer global availability, providing microbicides to the populations that need them most. Proof of principle for the use of transgenic plants as a production platform for a protein microbicide has recently been described (3) . In these studies, cyanovirin-N (CV-N), a microbicide that has previously demonstrated potent HIV-neutralizing activity and protection in a SHIV challenge study in macaques (4, 5) , was successfully expressed in transgenic tobacco plants.
Many monoclonal antibodies (mAbs) are also in preclinical development as microbicide candidates (6) . Of these, mAb 2G12 has been produced in transgenic maize and tobacco (7, 8) and is targeted for a phase I clinical trial in 2009 (http: ⁄ ⁄ www.pharma-planta.org). Another microbicidal antibody is mAb b12, a human monoclonal IgG1, which recognizes a conformational amino acid epitope on HIV gp120 (9, 10) and has a broader range of HIV neutralization, appropriate for disease control in sub-Saharan Africa (11) . Studies in macaques demonstrated that administration of mAb b12 either intravenously or topically to the vagina, conferred protection against vaginal challenge with SHIV-162P4 (6, 12) .
The eukaryotic nature of plant cells and the structural and functional similarities of the endomembrane system with mammalian cells (13, 14) facilitate the expression and assembly of complex multimeric molecules such as antibodies and thus provide possibilities for unique therapeutics not feasible in other expression systems. For example, the tetrameric secretory IgA is efficiently assembled in transgenic plants (15) ; furthermore, mAb fusion proteins resulting in immune complexes have been produced for the first time using plants (16) . Building on this experience, here we describe the plant expression of the microbicide mAb b12, and then the design, engineering and expression of a fusion molecule comprising mAb b12 with CV-N to produce a combined microbicidal candidate in an expression system suitable for large-scale economic production.
MATERIALS AND METHODS

Gene constructs, CV-N-specific antiserum, and HIV strains
The gene encoding CV-N (N30Q/P51G) in plasmid pET30b(ϩ), recombinant purified CV-N produced in Escherichia coli, and anti-CV-N polyclonal antisera were all kindly supplied by Biosyn Inc. (Baton Rouge, LA, USA). Additional anti-CV-N antisera were donated by the National Cancer Institute (Rockville, MD, USA). The plant expression vector pL32 and transgenic plants expressing CV-N were already available (3). mAb b12 cDNA was kindly provided by the Dr. Dennis Burton (The Scripps Research Institute, La Jolla, CA, USA). HIV-1 virus strains and purified recombinant proteins were obtained from the U.S. National Institutes of Health (NIH) repository (AIDS Research and Reference Reagent Program, Germantown, MD, USA) and the UK Medical Research Council (MRC) Centralised Facility for AIDS Reagents (Potters Bar, UK). The following recombinant gp120 preparations were used: IIIB-EVA607; W61D-CFAR EVA648; SF2-ARP629; CN54 -ARP683, and ZM96 ARP696. CV-N-resistant HIV IIIB was kindly provided by Dr. Qin Hu (St. George's, University of London, London, UK).
Cloning
Cloning of the b12 ␥ and chains into pL32
The genes encoding mAb b12 ␥ and chains were amplified by PCR. For the heavy chain, the forward primer 5Ј-ATACTC-GAGCGCTGCAGGTGTCCATCAG was used with the reverse primer 5Ј-GCAGAATTCTCATTTACCCGGAGACAGGGA designed to incorporate a 5Ј XhoI restriction site and a 3Ј EcoRI restriction site respectively. For the light chain, the forward primer 5Ј-ATACTCGAGCGCTGCAGGTGTCCATTGC was used with the reverse primer 5Ј-GCGCCGGAATTCACTAA-CACTCTCCCCTGTTGAAGCTCTTTGTGACGGGCGATCT-CAG designed to incorporate a 5Ј XhoI restriction site and a 3Ј EcoRI restriction site, respectively.
The resulting DNA fragments were purified and ligated into the XhoI and EcoRI sites of pL32, a derivative of vector pMON530 (17) .
Cloning of b12 ␥-chain/CV-N into pL32
The gene encoding CV-N (CV-N N30Q/P51G) was amplified by PCR using the forward primer 5Ј-GGCGGATCCGGTGGAG-GCGGTTCAGGCGGAGGTGGCTCTCTTGGTAAATTCTCCC-AGACCTGC-3Ј, designed to incorporate a 5Ј BamHI restriction site and part of the (GGGGS) 3 flexible linker, and the reverse primer 5Ј-CGGGAATTCTTATTCGTATTTCAGGGT-3Ј, designed to incorporate a 3Ј EcoRI restriction site. The b12 ␥-chain cDNA was used as a template and amplified by PCR with primers 5Ј-ATACTCGAGCGCTGCAGGTGTCCATCAG-3Ј to incorporate a 5Ј XhoI restriction site, and 5ЈCGCGGATCCGC-CACCGCCTTTACCCGGAGACAGG GAGAGGCT-3Ј to incorporate the remaining section of the (GGGGS) 3 flexible linker and a BamHI restriction site.
The resulting CV-N and b12 ␥-chain fragments were ligated into the XhoI and EcoRI sites of pL32, as above.
Transformations and crosses
The recombinant vectors were used to transform E. coli (DH5␣, Invitrogen, Carlsbad, CA, USA) by heat-shock transformation (18) before insertion into Agrobacterium tumefaciens (LBA4404, Invitrogen) by electroporation. Recombinant A. tumefaciens was used to transform Nicotiana tabacum (var. xanthii), as described previously (3, 19) .
Independent tobacco transformants were generated for each construct. Two of the resulting b12 ␥-chain/CV-N transgenic plants and two of the b12 ␥-chain transgenic plants were allowed to flower and fertilized with pollen from a b12 -chain transgenic plant. The resulting seed was germinated and leaf extracts of the progeny were analyzed for the expression of assembled mAb b12 or mAb b12/CV-N. Leaf extracts of plants were prepared by grinding ϳ250 mg leaf tissue/ml PBS with a plastic pestle in a microfuge tube and centrifuging at 20,000 g for 10 min at 4°C to remove plant debris. Resulting supernatants were used immediately or stored at Ϫ20°C.
Western blot analysis
A mixture of 12.5 l (at ϳ1.5 mg/ml of total soluble protein) of leaf extract and 7.5 l SDS-loading buffer (0.3M Tris-HCl, pH 6.8; 10% (w/v) SDS; 50% (v/v) glycerol; 0.125% (w/v) bromphenol blue) with or without ␤-mercaptoethanol was loaded onto SDS-polyacrylamide gels alongside a protein standard (Precision Plus; Bio-Rad, Hercules, CA, USA). The gels were blotted onto nitrocellulose membrane using a semidry transfer system (Hoefer TE70; Amersham Biosciences, Piscataway, NJ, USA) and blocked with 5% nonfat dried milk in TBS. Blots were incubated with a 1:1000 dilution of either anti-CV-N polyclonal rabbit serum, anti-human IgG ␥-chain sheep antiserum (The Binding Site, Birmingham, UK) or anti-human IgG -chain sheep antiserum (The Binding Site). After stringent washing, a horseradish peroxidaseconjugated anti-rabbit IgG antiserum (Sigma, St. Louis, MO, USA) or anti-sheep IgG antiserum (The Binding Site) diluted 1:1000 was applied. Antibody binding was detected using Phototope-HRP Western blot detection system (Cell Signaling Technology, Danvers, MA, USA).
ELISAs
gp120 binding ELISA
The binding ability to HIV-1 gp120 was assessed by ELISA based on the method of Boyd et al. (20) . Briefly, ELISA wells were coated with 100 ng of recombinant gp120 (HIV-1 IIIB unless otherwise stated; EVA607, MRC Centralised Facility for AIDS reagents, Potters Bar, UK). After washing and blocking of the plate, we added serial dilutions of samples. Binding was detected with a 1:1000 dilution of anti-human ␥-chain or anti-human -chain antiserum (The Binding Site). Horseradish peroxidase conjugated anti-sheep antibody (The Bind-ing Site) diluted 1:1000 was used as the secondary antibody. In the case of the denatured gp120 binding ELISA, gp120 IIIB was denatured prior to coating by boiling for 5 min in 1% SDS and 50 mM DTT, according to the method of Moore et al. (21) .
ELISAs to detect assembled b12 and b12/CV-N
Immunoplates (96-well Nunc Maxisorp; Nunc, Roskilde, Denmark) were coated with either anti-human IgG -chain or anti-human IgG ␥-chain antiserum (The Binding Site). After blocking with 2.5% (w/v) BSA, serial dilutions of samples were added. Assembled b12 or b12/CV-N was detected by a 1:1000 dilution of anti-human -chain antiserum (The Binding Site) or anti-CV-N polyclonal antiserum, respectively. Secondary antibody of anti-sheep IgG antisera or anti-rabbit IgG antiserum (The Binding Site) was added at a dilution of 1:1000.
Porcine thyroglobulin ELISA
ELISA plates were coated with 15 g/ml porcine thyroglobulin (Sigma) and blocked with 5% nonfat dried milk in water before the addition of samples. Detection of binding was performed with either HRPO-labeled anti-human -chain antiserum (The Binding Site) or rabbit anti-CV-N antiserum followed by HRPO-labeled anti-rabbit IgG antiserum (The Binding Site) at a dilution of 1:1000.
HIV-binding ELISA
CV-N-resistant HIV IIIB was inactivated by treatment with 1 mM aldrithiol 2(AT-2, Sigma) for 1 h at 37°C. Inactivated HIV was then used to coat an ELISA plate and blocked with 2.5% BSA. Serial dilutions of samples were added, and binding was detected using a 1:1000 dilution of anti-human IgG ␥-chain antiserum (The Binding Site) and anti-CV-N polyclonal antiserum. Secondary antibody of anti-sheep IgG antiserum or anti-rabbit IgG antiserum (The Binding Site) was added at a dilution of 1:1000. Coating of the plate by the CV-N-resistant HIV IIIB was confirmed by detecting directly with anti-gp120 antiserum (ARP401; UK National Institute for Biological Standards and Control, Potters Bar, UK) at a dilution of 1:500 and using a secondary antibody of anti-sheep IgG antiserum (The Binding Site) diluted 1:1000.
In all cases, HRPO-bound antibodies were developed using 3,3Ј,5,5Ј-tetramethylbenzidine (TMB) substrate (Sigma) and reading at 450 nm (Tecan Sunrise; Tecan, Reading, UK).
HIV-neutralizing assay
HIV-neutralizing activity was assessed by luciferase production by TZM-bl cells, which contain the luciferase gene under the control of the HIV-1 promoter (22) . Plant leaf tissue was ground at 250 mg/ml in medium (10% DMEM, 10% v/v heat-inactivated fetal calf serum, 100 U/ml penicillin, 0.1 mg/ml streptomycin, and 2 mM l-glutamine). After centrifuging to remove plant debris, serial dilutions were incubated for 1 h at 37°C with 5% CO 2 with HIV (BaL) (of which the appropriate dilution to provide adequate infection had been ascertained by a previous titration). The plant extract and virus mixture were transferred to a 96-well plate previously seeded with 5 ϫ 10 4 TZM-bl cells/well (8129; NIH AIDS Research and Reference Reagent Program) and incubated at 37°C with 5% CO 2 for up to 24 h. The cells were washed with PBS, and luciferase production was assessed by a luciferase assay kit (Promega, Madison, WI, USA). Briefly, cells were lysed with 100 l/well of lysis buffer (diluted 1:5 in water), and the plates were frozen at Ϫ80°C for a minimum of 2 h. After thawing, 50 l of lysed cells were transferred to a white 96-well plate, and 50 l/well of luciferase mixture was added (luciferase buffer and luciferase assay substrate mixed according to manufacturer's instructions). Luciferase production was immediately assessed by a Synergy-HT ELISA plate reader (Bio-Tek Instruments, Inc., Winooski, VT, USA) using a Lum/E filter with a sensitivity threshold of 150 nm. The inhibition curves obtained in these assays were subject to linear regression analysis using GraphPad Prism (San Diego, CA, USA), based on a sigmoidal dose-response equation and constrained to a top value of 100% and a bottom value of 0. The resulting line equation, which best fitted the inhibition curve, was used to calculate a value for the 50% effective concentration of the sample (EC 50 ).
RESULTS
Generation of mAb b12 and b12/CVN transgenic plants
The light-and heavy-chain genes of mAb b12 were subcloned into plant expression vectors. These were introduced separately into plants by agrobacteriummediated transformation (19) , and transgenic plants were regenerated as described. mAb b12 IgG transgenic plants were produced by cross-fertilization between b12 and b12 ␥ transgenic plants. These primary transgenic plants had been identified by immunoglobulin-chain-specific ELISA (data not shown), and the highest-expressing lines were selected and grown to maturity. After cross-fertilization, second-generation transgenic plant lines were screened for coexpression of mAb b12 light and heavy chains, by measuring binding to CHO recombinant HIV gp120 (from a clade B strain, W61D). Results from a representative screen are shown in Fig. 1A . A human anti-HIV env mAb (D30) was used as a positive control. Extract from a nontransgenic wild-type plant was included as a negative control, and no cross-reactivity was detected. Seven of 10 plants clearly demonstrated gp120-binding activity. Three mAb b12-expressing plants were selected, and the binding to gp120 from three HIV strains [2 Clade C (ZM96, CN54) and 1 Clade B (SF2)] is shown in Fig. 1B . In all cases, there was significant binding to antigen above the background signal from extracts from nontransgenic wild-type plants, although in the case of CN54, the signal was rather weak.
The mAb b12/CV-N fusion protein was achieved by first expressing a fusion heavy chain in a transgenic plant, in which CV-N was expressed at the C terminus of the mAb b12 heavy chain. This transgenic plant line was then cross-fertilized with the existing mAb b12 -chain transgenic plant line. It was predicted that assembly of the recombinant light and heavy chains would result in a mAb b12/CV-N fusion protein with the potential to bind two gp120 molecules by its CV-N moieties and a further two gp120 molecules via its mAb b12 Fab moieties ( Fig. 2A) . Transgenic plants express-ing the b12 ␥-chain/CV-N fusion protein were first identified by screening for CV-N binding in a gp120-binding ELISA (results not shown). Two b12 ␥-chain/ CV-N transgenic plants were selected and cross-pollinated with each of two transgenic tobacco plants expressing mAb b12 chain. The resulting seed was germinated, and the progeny plants were screened for the coexpression of both transgenes by a gp120-binding ELISA, which detects the presence of the chain, as well as assesses functional gp120 binding (Fig. 2B) .
Nine of the 10 plants tested demonstrated the presence of functional fusion protein. Both parental plant lines (b12 ␥ chain/CV-N and b12 ), as well as wild-type plants and plants expressing CV-N alone, were included as negative controls, and no binding was detected.
In an alternative ELISA, an anti--chain antiserum was used for capture, and bound protein was then detected with an anti-CV-N-specific antiserum (Fig. 2C) . A strongly positive signal was detected in the 3 mAb b12/CV-N plant extracts, but not in the extract from [1] [2] [3] [4] [5] [6] [7] [8] [9] 12) and are means of duplicate wells. mAb D30 was used as a positive control, a wild-type plant extract was used as a negative control. B) mAb b12 transgenic plant extracts were tested for gp120-binding activity. ELISA plates were coated with gp120 from 3 different strains (SF-2, ZM96 and CN54), and bound fusion protein was detected with HRPO anti-human IgG ␥-chain antiserum. Three mAb b12 transgenic plants are shown (plants 1, 3, 12) . Wild-type plant extract was included as a negative control (WT).
wild-type nontransgenic, mAb b12 transgenic, or CV-N transgenic plants.
One of the positive plants was self-fertilized to produce seed stocks, and resulting progeny were rescreened by the same gp120-binding ELISA (not shown) to identify two transgenic plants that were subsequently used for study, as well as the provision of daughter plants.
Plant-derived mAb b12/CV-N fusion protein exhibited concentration-dependent binding to gp120 from four HIV-1 clade B strains (IIIB, W61D, SF-2, and MN) and one clade C strain (ZM96) (Fig. 2D) . Wild-type plant extract did not demonstrate binding to any of the different gp120 proteins. Extract from a mAb b12 transgenic plant was also included as a positive control for gp120 IIIB binding.
Western blot analysis of mAb b12 and b12/CV-N transgenic plants
Western blot analysis was performed to detect both mAb b12 and CV-N expression in the mAb b12 and b12/CV-N transgenic plant extracts (Fig. 3) . Under reducing conditions, the human chain was detected at the expected M r (25,000) in both plant lines, but not the wild-type nontransgenic plant extract (Fig. 3A) . In addition, there was an M r 12,000 band that probably represents a degradation product, as it was not present in the human IgG control sample. With an anti-heavychain-specific antiserum, a band of ϳ52,000 was observed in the mAb b12 transgenic plant extract (Fig. 3B,  lane 2) , which was the same size as that detected in the Results are means of duplicate wells on the ELISA plate; 2 dilutions are shown. Extracts from each of the parental plants (b12␥/CV-N and b12 ) were included as negative controls. Extracts from a CV-N transgenic plant (CV-N plant) and a wild-type plant (wildtype) were also included as negative controls. C) Confirmation of mAb b12/CV-N fusion protein assembly. ELISA plates were coated with an anti-antiserum, and bound fusion protein was detected with a rabbit anti-CV-N polyclonal antiserum, followed by an HRPO-labeled anti-rabbit IgG antiserum. Results are means Ϯ sd of triplicate wells in a representative experiment. Dilution curves are shown for 3 mAb b12/CV-N transgenic plants. E. coli-derived purified CV-N, wild-type plant extract, and extract from a mAb b12 transgenic plant are included as negative controls. D) HIV gp120-binding activity of mAb b12/CV-N transgenic plant extracts. ELISA plates were coated with gp120 from 5 different HIV strains (IIIB, W61D, SF-2, MN, and ZM96), and bound fusion protein was detected with anti-human IgG ␥-chain antiserum. Wild-type plant extract was included as a negative control (WT) and extract from a mAb b12 transgenic plant was included for gp120 IIIB as a positive control (b12). Results are means Ϯ sd of triplicate wells in a representative experiment.
human IgG control (Fig. 3B, lane 1) . In the mAb b12/CV-N plant line, a slightly larger immunoreactive band was detected with an approximate M r of 63,000 (Fig. 3B, lane 4) , which is the expected relative mass for the fusion chain (52,000 for the mAb b12 ␥ chain and 11,000 for CV-N). A smaller band, M r 37,000, was observed in the mAb b12 plant extract, which is likely to be a degradation product, and this may correspond to the M r ϳ 48,000 band in the mAb b12/CV-N plant extract. If so, it suggests the presence of a major exposed cleavage site within the constant region of the mAb b12 heavy chain.
Under nonreducing conditions, assembly of IgG was confirmed in the mAb b12 transgenic plant line (Fig.  3C) . The plant-derived antibody (Fig. 3C, lane 1) had the same M r as the human IgG-positive control (Fig. 3C,  lane 2) . Assembly of a high-molecular-mass complex was also observed in two mAb b12/CV-N plant lines [ Fig. 3D, lanes 4 (arrow) and 6], which was not seen in the negative control plant extract (Fig. 3D, lane 2 ) or in the sample from a b12 ␥-chain/CV-N transgenic plant (Fig. 3D, lane 3) . In the latter, two predominant bands were detected that are consistent with b12 ␥-chain/ CV-N dimers and trimers. There was a notable difference in the band intensity from the b12 ␥-chain/CV-N sample, compared with the mAb b12/CV-N samples, suggesting much higher levels of accumulation of the heavy-chain fusion protein alone.
A Western blot detecting CV-N under reducing conditions demonstrated four major bands in the mAb b12/CV-N transgenic plant extracts at M r ϳ 11,000, 25,000, 50,000, and 63,000 (Fig. 3E, lanes 2-4) . The topmost band (Fig. 3E, M r ϳ63K) is consistent with the expected size for the b12 ␥-chain/CV-N fusion protein.
The presence of the three other major bands is indicative of proteolytic cleavage, with the 11,000 band possibly representing the CV-N monomer. E. coli-derived purified CV-N (Fig. 3E, lane 1) and extract from a CV-N transgenic plant (Fig. 3E, lane 5) were used as controls. The 11,000 band indicative of CV-N was observed in both cases; however, none of the highermolecular-mass bands present in the b12/CV-N transgenic plant extracts were seen in these controls.
Under nonreducing conditions, probing with anti-CV-N-specific antiserum revealed an absence of low M r bands between 11,000 and 61,000 and assembly into higher-molecular-mass forms, consistent with assembly of the mAb b12/CV-N fusion protein (Fig. 3F) . The extract from a mAb b12/CV-N plant (Fig. 3F, lane 2) contains a band (Fig. 3F, arrow) that corresponds to the assembled fusion protein and is the same size as the immunoreactive band detected with anti-heavy-chain antiserum in Fig. 3D . The nontransgenic plant extract (lane 1) contained no immunoreactive bands, and the control recombinant CV-N sample contained only low-molecularmass species, consistent with previous findings (3).
Functionality of the mAb b12/CV-N fusion protein
The results from the ELISA and Western blot analyses provided evidence for assembly of molecular complexes and HIV envelope antigen binding. The next step was to demonstrate the functional activity of each microbicidal moiety in the mAb b12/CV-N fusion protein. This protein has the potential to bind gp120 through two mechanisms: via the mAb b12 moiety, binding to its conformational amino acid epitope, or via the CV-N moiety, binding to high-mannose residues on the surface of gp120. We investigated the binding of mAb b12/CV-N fusion protein to heat-denatured HIV gp120, which should eliminate the mAb b12 epitope, but not the CV-N recognition sites. We also investigated binding to porcine thyroglobulin, a glycoprotein that displays Man-8 and Man-9 residues like those that are recognized on HIV gp120 by CV-N. Finally, we investigated the fusion protein binding to a CV-N-resistant HIV strain, in which the relevant glycosylation sites for CV-N binding were absent (23) , resulting in diminished CV-N affinity (24) .
A gp120-binding ELISA was performed using both native gp120 and denatured gp120 as the capture antigen (Fig. 4A) . Extracts from a mAb b12/CV-N . ELISA plates were coated with either native or denatured gp120, and binding was detected by anti-human ␥-chain antiserum. Results for extracts from a mAb b12 plant, a mAb b12/CV-N transgenic plant, and a wild-type nontransgenic control are shown and are means Ϯ sd of triplicate wells in a representative experiment. B) Binding of b12/CV-N fusion protein to porcine thyroglobulin glycoprotein. ELISA plates were coated with porcine thyroglobulin, and bound fusion protein in the mAb b12/CV-N plant extracts was detected with either anti-human -chain antiserum (left panel) or anti-CV-N antiserum (right panel). Wild-type plant extract was used as a negative control. Purified IgG at a top concentration of 100 ng/ml was used as a negative control (IgG). E. coli-derived purified CV-N at a top concentration of 125 ng/ml was used as a negative control for anti-human -chain detection and a positive control for anti-CV-N detection (CV-N). A mAb b12 plant extract was used as a negative control. Results are means of duplicate wells from a representative experiment. transgenic plant and a mAb b12 transgenic plant were compared. The plant extracts contained the equivalent of 2.45 and 7.35 g/ml mAb b12, respectively, as determined using a quantitative IgG sandwich ELISA against a standard human IgG preparation of known concentration (not shown). Both bound to native gp120 in a concentration-dependent manner (Fig. 4A, left  panel) , as previously demonstrated. However, when the capture gp120 antigen was heat denatured prior to ELISA plate coating (Fig. 4A, right panel) , binding of the mAb b12 transgenic plant extract was abolished (a reduction in binding of 96%), whereas binding of the mAb b12/CV-N transgenic plant extract was only diminished by 25%. No binding to either native or denatured gp120 was observed for wild-type plant extract used as a negative control. These results are consistent with the suggestion that heat denaturation destroys the mAb b12 epitope and that the residual binding of mAb b12/CV-N fusion protein to denatured gp120 through its CV-N moieties.
Further evidence that the CV-N moiety of the mAb b12/CV-N fusion protein was functional was provided by investigating binding of the mAb b12/CV-N transgenic plant extracts to porcine thyroglobulin, a glycoprotein that is reported to contain Man-9 and Man-8 (D1D3) glycans (25) , which are recognized by CV-N, but no HIV epitopes. In these experiments (Fig. 4B) , no antigen binding was detected using mAb b12 alone (Fig. 4B, left panel) . The control CV-N did bind, but this could only be detected using an anti-CV-N antiserum (Fig. 4B, right panel) and not with an antihuman -chain antiserum (Fig. 4B, left panel) . In contrast, concentration-dependent binding was detected in the extracts from mAb b12/CV-N transgenic plants, using both anti-CV-N and anti-human -chain antisera (Fig. 4B, both panels) , demonstrating the activity of the CV-N moiety within the mAb b12/CV-N fusion protein.
To assess the functionality of the b12 moiety of the mAb b12/CV-N fusion protein, a CV-N-resistant strain of HIV IIIB was used (23) . This mutant was characterized as a deglycosylation mutant with greatly reduced binding to CV-N (24) and increased resistance to CV-N neutralization. Inactivated CV-N-resistant HIV was coated on ELISA plates, and binding of mAb b12 and mAb b12/CV-N transgenic plant extracts was detected by anti-human ␥-chain antiserum or anti-CV-N polyclonal antiserum (Fig. 5) . Coating of the plate was confirmed by detection with anti-gp120 (positive control). Concentrations of mAb b12 and CV-N in the plant extracts were calculated prior to the assay by ELISA (not shown) and standardized in this experiment for direct comparison. mAb b12/CV-N transgenic plant extract demonstrated binding to the CV-N-resistant HIV IIIB using either anti-␥-chain antisera (Fig. 5,  left panel) or anti-CV-N antisera (Fig. 5, right panel) . mAb b12 transgenic plant extract at the equivalent IgG concentration also demonstrated binding (Fig. 5, left  panel) , whereas a plant extract containing the equivalent CV-N concentration and wild-type plant extract did not demonstrate any binding (Fig. 5, right panel) .
HIV-neutralizing activity of mAb b12/CV-N and mAb b12 transgenic plant extracts
Assays were performed to assess the HIV-neutralizing activity of the mAb b12 and b12/CV-N transgenic plant extracts (Fig. 6) . The HIV-neutralizing activity of a mAb b12 transgenic plant extract is shown in Fig. 6A . CV-N transgenic and wild-type plant extracts are included as positive and negative controls, respectively. The EC 50 value was determined from the inhibition curve; for this representative mAb b12 transgenic plant, EC 50 ϭ 3.34 g/ml. The mean Ϯ sd EC 50 value was subsequently calculated from this and three further plant samples: 2.59 Ϯ 0.8 g/ml.
The neutralization data for four mAb b12/CV-N transgenic plants are shown in Fig. 6B , C. The data were adjusted for both CV-N concentration (Fig. 6B ) and IgG concentration (Fig. 6C) . All mAb b12/CV-N transgenic plants displayed concentration-dependent HIV neutralizing activity. E. coli-derived purified CV-N (Fig.  6B ) and the extract from a transgenic plant expressing mAb b12 alone (Fig. 6C) were included for comparison and also demonstrated HIV-neutralizing activity in a concentration-dependent manner. Wild-type plant extract was included as a negative control and did not exhibit any anti-HIV activity.
EC 50 values were determined from the inhibition curves from a total of six mAb b12/CV-N transgenic plants, and all demonstrated increased potency compared to the E. coli-derived purified CV-N and the b12 transgenic plant extract. The mAb b12/CV-N transgenic plant extracts had a mean EC 50 of 66.5 Ϯ 18.2 ng of CV-N/ml compared to 148.5 ng/ml for the E. coli-derived purified CV-N, and a mean EC 50 of 20 Ϯ 14.3 ng of IgG/ml compared to 831 ng/ml for the b12 transgenic plant extract (in this assay).
DISCUSSION
Topical microbicides represent one of the most promising approaches toward controlling new HIV infection rates in the short term. Their success will depend on many factors, including availability, cost, ease of use, and patient acceptability. There are currently a number of good protein microbicide candidates, but the issues of manufacturing, scalability, and cost are possibly more pertinent than those for other microbicidal molecules, such as the replication inhibitors (e.g., nonnucleotide reverse-transcription inhibitors), which can be chemically synthesized. There is a further complication that a microbicide product may well require a combination of two or three molecules, in order to minimize the risk of viral adaptation and the generation of resistant strains and to provide sufficient crossclade protection. Thus, feasibility of manufacture is a critical consideration.
We have previously reported expression of one of the protein microbicides used in this study-cyanovirin-N, in transgenic plants (3) . The production levels of functional CV-N were high, and the study represented proof of concept for the use of a transgenic plant system. In this study, we describe the production of a further protein microbicide candidate, mAb b12, in transgenic tobacco plants. We also anticipate the need for a microbicide cocktail by designing and expressing a single multimeric recombinant protein that has the functional activities of both mAb b12 and CV-N. These two molecules both neutralize HIV but do not compete with each other as b12 binds a protein epitope, whereas CV-N binds a glycan epitope (26) .
Transgenic tobacco plants expressing the HIVneutralizing mAb b12 were successfully generated through the cross-fertilization of b12 ␥ and b12 transgenic plants. The mAb b12 in these transgenic plant extracts was efficiently assembled, as shown by Western blot and ELISA, as well as functional for gp120 binding.
A mAb b12/CV-N fusion protein was generated through the cross fertilization of two parent transgenic plants containing different subunits (mAb b12 ␥ chain/ CV-N and mAb b12 chain). From the resulting progeny, transgenic plants were identified that demonstrated the assembly of functional mAb b12/CV-N fusion protein. Western blot analysis also revealed a pattern of cleavage of the mAb b12/CV-N fusion protein that correlated to some extent with that demon- strated with plant-derived b12, suggesting that cleavage may occur at specific sites in the mAb b12 ␥ chain. Such cleavage has implications for the overall levels of the fusion protein available for purification, and strategies to minimize degradation in planta will be the subject of future studies.
Functional activity of the mAb b12/CV-N fusion protein was determined by a number of assays. The binding to gp120 from five different strains of HIV was confirmed by ELISA. In addition, we attempted to demonstrate the binding activity of each component of the mAb b12/CV-N fusion protein. mAb b12 recognizes a conformational epitope (9) , and binding to gp120 was almost completely abolished by denaturation of the antigen. In contrast, the retention of binding activity by mAb b12/CV-N to denatured gp120 (in which the surface glycans would be unchanged) indicated functionality of the CV-N moiety in the fusion protein. This was supported by the demonstration of binding to porcine thyroglobulin, a glycoprotein that shares cross-reactive glycoepitopes with HIV gp120, but is not recognized by mAb b12 alone. Functionality of the mAb b12 moiety was determined by demonstrating binding to a CV-N-resistant HIV strain, in which mutagenesis had resulted in deglycosylation of the major binding sites for CV-N.
HIV neutralization activity of the plant-derived mAb b12 and the b12/CV-N fusion protein was assessed by a luciferase assay. In both cases, anti-HIV activity was observed in a concentration-dependent manner. For plant-derived mAb b12, an EC 50 of 2.5 g/ml was determined, which is consistent with previously published values for mAb b12 produced by conventional systems (27, 28) .
The HIV neutralization assay data from the mAb b12/CV-N fusion protein were corrected for both IgG and CV-N concentrations. In terms of IgG, the plant-derived mAb b12/CV-N fusion protein demonstrated an EC 50 of 20 ng/ml. When corrected for CV-N concentration, an EC 50 of 66.5 ng/ml was determined. Thus, in both cases the mAb b12/CV-N fusion protein demonstrated enhanced potency compared to the individual microbicide (the EC 50 for CV-N was 148.5 ng/ml). This preliminary evidence that the fusion protein is more potent than its component moieties is promising, and studies are under way to determine whether the enhanced potency is due to additive or synergistic effects.
The enhanced potency of the mAb b12/CV-N fusion protein might arise through a number of mechanisms: 1) the fusion molecule has four potential gp120 binding sites, and therefore would have greater gp120 binding avidity compared to its individual components; 2) the ability of the fusion protein to target four gp120 molecules may result in aggregation of the viral particles or cross linking of gp120 on one virus particle by binding to either end of the fusion protein; or 3) the ability of either moiety of the fusion protein to aid the targeting of its partner moiety to gp120.
It is likely that preventing HIV transmission in vivo will require a combination of microbicide products to provide broad viral coverage and prevent the development of resistant HIV strains. The cost of manufacturing more than one product is likely to be prohibitive, so the development of new strategies is required. We have explored this issue by fusing two protein microbicides and expressing them in planta and demonstrated the feasibility and potential of this approach. Such fusion proteins could represent a new generation of valuable microbicide products.
